Qiagen N.V. (QGEN)
|Net Income (ttm)||448.58M|
|Trading Day||May 10|
|Day's Range||46.80 - 47.79|
|52-Week Range||41.98 - 59.00|
QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.
Qiagen NV (NYSE: QGEN) on Monday after-hours reported first-quarter revenue growth of 52% Y/Y to $567.2 million, exceeding prior guidance and beating analyst consensus by $9.68 million. Adjusted EPS $0....
Qiagen (QGEN) delivered earnings and revenue surprises of 4.76% and 2.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
U.S.-German genetic testing specialist Qiagen reported slightly better-than-expected quarterly earnings on Monday as sales growth for non-coronavirus products added to high demand for its COVID-19 testi...
QIAGEN Exceeds Outlook in First Quarter 2021 Results, Reaffirms Sales Growth and Profitability Outlook for Full-Year ...
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #earnings--QIAGEN exceeds outlook in first quarter 2021 results, reaffirms sales growth and profitability outlook for full-year 2021
QIAGEN Announces EZ2 Connect Instrument Line for Automated Sample Processing in Research, Forensics and Diagnostics
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN announces EZ2 Connect instrument line for automated sample processing in research, forensics and diagnostics
QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON...
HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN with DiaSorin, announce the launch of LIAISON® LymeDetect® Assay based on QuantiFERON technology for early diagnosis of Lyme Borreliosis
QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Ca...
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN launches artus Prep&Amp as CE-marked SARS-CoV-2 test offering up to threefold increase in daily lab testing capacity
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to Report First Quarter 2021 Results
Investors continue to be optimistic about QIAGEN (QGEN) on the back of product launches and impressive geographical growth.
QGEN vs. TECH: Which Stock Is the Better Value Option?
Here we look at three stocks, OMI, HOLX and QGEN, that investors can add to their watchlist backed by robust long-term prospects.
QIAGEN's (QGEN) latest kit is likely to significantly reduce library turnaround times and plastics usage, thus allowing more accurate detection and quantification of molecular variants.
QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic Surveillance
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN adds to COVID-19 portfolio with new ultra-fast sequencing solution for high-throughput genomic surveillance
QIAGEN's (QGEN) new NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test strengthens the company's portfolio in PCR testing, while becoming a crucial diagnostic tool for the flu season and the pandemic.
QIAGEN Receives FDA Emergency Use Authorization for NeuMoDx Multiplex Test Expanding COVID-19 Portfolio
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN receives FDA Emergency Use Authorization for NeuMoDx multiplex test expanding COVID-19 portfolio
QIAGEN (QGEN) expands specimen types that can be used on the existing NeuMoDx SARSCoV-2 test.
QIAGEN's (QGEN) QIAsphere cloud-based platform will enhance QIAstat-Dx's potential by offering remote services round the clock to improve testing continuity.
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN announces 20-F annual report filing for 2020 results
QIAGEN Launches QIAsphere Cloud-Based Connectivity Solution to Enhance QIAstat-Dx Capabilities in Digital Diagnostics
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN--QIAGEN launches QIAsphere cloud-based connectivity solution to enhance QIAstat-Dx capabilities in digital diagnostics
QIAGEN's (QGEN) QIAcube Connect MDx platform can be used with more than 140 standard protocols and it ensures complete consistency of the purification of multiple sample types.
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN launches QIAcube Connect MDx platform for automated sample processing in diagnostic labs
Qiagen NV (NYSE: QGEN) and Inovio Pharmaceuticals Inc (NASDAQ: INO) expanded their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products usin...
QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO's ...
PLYMOUTH MEETING, Pa. & GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN and INOVIO expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's...
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN expands Supervisory Board with appointment of a new member
QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.
Qiagen (QGEN) delivered earnings and revenue surprises of 3.03% and 3.51%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Qiagen (NYSE:QGEN) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 41.67% year over year to $0.68, which beat the est...
QIAGEN Beats Outlook for Fourth Quarter and Full-Year 2020, Reaffirms Expectations for Further Growth in 2021
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN beats outlook for fourth quarter and full-year 2020, reaffirms expectations for further growth in 2021
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN Adds dPCR Platform QIAcuity to Growing Portfolio of COVID-19 Testing Solutions for Wastewater and Mutation Tes...
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN adds dPCR platform QIAcuity to growing portfolio of COVID-19 testing solutions for wastewater and mutation testing
QIAGEN (QGEN) along with with Australia-based digital diagnostics company, Ellume develops QIAreach SARS-CoV-2 Antigen Test.
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to Report Fourth Quarter and Full-Year 2020 Results
QIAGEN Plans to Resubmit EUA Submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the First Quarter of 2021
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the first quarter of 2021
QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus
VENLO, The Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN announces appointment of new Supervisory Board member
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
QIAGEN Underlines and Innovates Its Commitment to Sustainability With a EUR 400mn Sustainability-linked Credit Facility
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN underlines and innovates its commitment to sustainability with a EUR 400mn sustainability-linked credit facility
QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds and Price to Non-US Holders to Sell...
VENLO, The Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the successful pricing of the following series of transac...
QIAGEN's (QGEN) latest RUO solution is expected to provide better insights into the course of the COVID-19 infection and aid in vaccine development and deployment.
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN increases outlook for 2020 and 2021
QIAGEN to Launch QuantiFERON SARS-CoV-2 For Research Into Causes, Spread and Control of COVID-19 Through T-cell Response
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN--QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response
Much healthcare investment attention is dominated by COVID-19, but other needs persist, including diagnostics provision and research. One investor asks about QIAGEN's current prospects and competitors. ...
Is QIAGEN (QGEN) a great pick from the value investor's perspective right now? Read on to know more.
Qiagen has been a beneficiary of COVID related tailwinds particularly as related to COVID testing, which has driven strong revenue growth and profitability. Several new products set to come to market in...
QIAGEN (QGEN) aims to leverage its global reach and position in CDx and HPV testing by collaborating with BioNTech.
QIAGEN Collaborates with BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of ...
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN--QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
QIAGEN (QGEN) aims to expand its NeuMoDx testing menu with the latest test launch and label extension.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sa... [Read more...]
Diagnostics & Research
|IPO Date |
Jun 28, 1996
|Stock Exchange |
|Ticker Symbol |
According to 13 analysts, the average rating for Qiagen stock is "Buy." The 12-month stock price forecast is 58.87, which is an increase of 25.55% from the latest price.